EDUARDO
DÍAZ-RUBIO GARCÍA
Researcher to 2020
![Foto de EDUARDO](/img/nophoto.png)
![Foto de Hospital Universitario Reina Sofia](/img/noimage_org.png)
Hospital Universitario Reina Sofia
Córdoba, EspañaPublications in collaboration with researchers from Hospital Universitario Reina Sofia (43)
2023
2022
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
2021
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain
Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26
2020
-
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116
-
Treatment patterns for metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462
2019
-
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
Scientific Reports, Vol. 9, Núm. 1
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
2018
-
Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii611-viii612
-
Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612
-
Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study
Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618
-
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470
-
The quality oncology practice initiative program: Experience in Spain
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii570-viii571
2016
-
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology, Vol. 27, Núm. 8, pp. 1386-1422
2015
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
-
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
Molecular Diagnosis and Therapy, Vol. 19, Núm. 6, pp. 397-408
2012
-
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study
Oncologist, Vol. 17, Núm. 7, pp. 947-955
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study
Oncologist, Vol. 17, Núm. 3, pp. 339-345